vosaroxin and amonafide

vosaroxin has been researched along with amonafide* in 1 studies

Other Studies

1 other study(ies) available for vosaroxin and amonafide

ArticleYear
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
    Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:4

    Do patients with therapy-related acute myeloid leukemia (t-AML) have a poor prognosis independent of other predictive variables such as cytogenetics or molecular determinants? Limited data exist to answer this question in part because t-AML is often considered together with AML following myelodysplastic syndromes (MDS) in the category of secondary AML. This discussion provides some insight, based primarily on two published retrospective reviews of the German cooperative groups, into the question of whether t-AML is an independent adverse variable.

    Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles

2011